IMMX - חוב לטווח קצר להון Immix

Immix Biopharma, Inc. (IMMX) is accelerating drug development through AI and automated synthesis, although medical personnel remain indispensable during trials. The company is implementing closed cultivation platforms to eliminate defects in drug production. This price action chart on GURU.Markets shows that the metric is 0.00. Meanwhile, the primary research centers are based in California, while vaccine production is delegated to external CDMO bio-factories.

This ratio determines the company's dependence on obligations with a maturity of up to one year relative to its equity, signaling liquidity risks or aggressive growth financing. Analyzing the share of short-term loans in equity allows for an assessment of the stability of Immix Biopharma, Inc. (IMMX), whose expenditures on AI-driven drug synthesis automation must be balanced against costly clinical trials.